170 related articles for article (PubMed ID: 24160940)
1. Anti-B cell antibody therapies for inflammatory rheumatic diseases.
Faurschou M; Jayne DR
Annu Rev Med; 2014; 65():263-78. PubMed ID: 24160940
[TBL] [Abstract][Full Text] [Related]
2. The potential utility of B cell-directed biologic therapy in autoimmune diseases.
Arkfeld DG
Rheumatol Int; 2008 Jan; 28(3):205-15. PubMed ID: 17957371
[TBL] [Abstract][Full Text] [Related]
3. Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.
Vossenkämper A; Lutalo PM; Spencer J
Clin Exp Immunol; 2012 Jan; 167(1):7-14. PubMed ID: 22132879
[TBL] [Abstract][Full Text] [Related]
4. B-cell-depleting therapy in systemic lupus erythematosus.
Ramos-Casals M; Sanz I; Bosch X; Stone JH; Khamashta MA
Am J Med; 2012 Apr; 125(4):327-36. PubMed ID: 22444096
[TBL] [Abstract][Full Text] [Related]
5. Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.
Levesque MC
Clin Exp Immunol; 2009 Aug; 157(2):198-208. PubMed ID: 19604259
[TBL] [Abstract][Full Text] [Related]
6. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside.
Stohl W; Scholz JL; Cancro MP
Curr Opin Rheumatol; 2011 May; 23(3):305-10. PubMed ID: 21330926
[TBL] [Abstract][Full Text] [Related]
7. Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases.
Long Z; Zeng L; He Q; Yang K; Xiang W; Ren X; Deng Y; Chen H
Front Immunol; 2023; 14():1150661. PubMed ID: 37809072
[TBL] [Abstract][Full Text] [Related]
8. Designer drugs: the biologic therapies.
Johnston S
Clin Med (Lond); 2006; 6(4):337-43. PubMed ID: 16956136
[No Abstract] [Full Text] [Related]
9. The efficacy of novel B cell biologics as the future of SLE treatment: a review.
Kamal A; Khamashta M
Autoimmun Rev; 2014 Nov; 13(11):1094-101. PubMed ID: 25149393
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
11. Biologic treatment in Sjögren's syndrome.
Sada PR; Isenberg D; Ciurtin C
Rheumatology (Oxford); 2015 Feb; 54(2):219-30. PubMed ID: 25342375
[TBL] [Abstract][Full Text] [Related]
12. The epidemiology of Sjögren's syndrome.
Patel R; Shahane A
Clin Epidemiol; 2014; 6():247-55. PubMed ID: 25114590
[TBL] [Abstract][Full Text] [Related]
13. Sjögren's syndrome: where do we stand, and where shall we go?
Cornec D; Jamin C; Pers JO
J Autoimmun; 2014 Jun; 51():109-14. PubMed ID: 24612946
[TBL] [Abstract][Full Text] [Related]
14. Sjögren's syndrome: an update on epidemiology and current insights on pathophysiology.
Reksten TR; Jonsson MV
Oral Maxillofac Surg Clin North Am; 2014 Feb; 26(1):1-12. PubMed ID: 24287189
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
Lenert A; Lenert P
Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
[TBL] [Abstract][Full Text] [Related]
16. Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank.
Rasmussen SM; Bilgrau AE; Schmitz A; Falgreen S; Bergkvist KS; Tramm AM; Baech J; Jacobsen CL; Gaihede M; Kjeldsen MK; Bødker JS; Dybkaer K; Bøgsted M; Johnsen HE
Cytometry B Clin Cytom; 2015 Jan; 88(1):40-9. PubMed ID: 25327569
[TBL] [Abstract][Full Text] [Related]
17. Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus.
Specchia ML; de Waure C; Gualano MR; Doria A; Turchetti G; Pippo L; Di Nardo F; Capizzi S; Cadeddu C; Kheiraoui F; Iaccarino L; Pierotti F; Palla I; Veneziano MA; Gliubizzi D; Sferrazza A; Nicolotti N; Porcasi R; La Torre G; Di Pietro ML; Ricciardi W
Biomed Res Int; 2014; 2014():704207. PubMed ID: 25243173
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
Stohl W
Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
[TBL] [Abstract][Full Text] [Related]
19. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab plus cyclosporine treatment of the autoimmune hemolytic anemia in an adult bowel transplant.
Lauro A; Stanzani M; Finelli C; Zanfi C; Morelli MC; Pasqualini E; Dazzi A; Ravaioli M; Di Simone M; Giudice V; Pironi L; Pinna AD
Case Rep Transplant; 2014; 2014():262953. PubMed ID: 25177510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
